Icosavax logo

Icosavax

Public Company
Seattle

Icosavax develops virus-like particle vaccines targeting respiratory viruses such as RSV, hMPV, and COVID-19. Its platform uses computational protein design and virus-like particle scaffolds to create experimental vaccines intended to be shelf-stable and advance to clinical trials.

Facts

HQ
Seattle
Sectors
Biotechnology, Vaccines, Life Sciences
Status
Public Company
Stage
Public
Members see funding amounts.
.

Is this your organization? Claim it

  • Completed an acquisition or disposition Feb 20, 2024
  • Leadership or executive-pay change Feb 20, 2024
  • Signed a material agreement Dec 12, 2023
  • Signed a material agreement May 23, 2023
  • Leadership or executive-pay change Feb 11, 2022
  • Leadership or executive-pay change Jan 5, 2022
  • Signed a material agreement Dec 16, 2021
  • Filed to go public Jul 7, 2021

People